Table 1.

Biodistribution of ^99mTc-RGD-Lys-(Arg¹¹)CCMSH in B16/F1 murine melanoma-bearing C57 mice. The data was presented as percent injected dose/gram or as percent injected dose (mean ± SD, n=5)

Tissue	0.5 h	2 h	2 h NDP blockade	2 h RGD blockade	4 h	24 h
	Percentage Injected Dose/gram (%ID/g)
Tumor	11.06 ± 1.41	14.83 ± 2.94	1.81 ± 0.64*	10.50 ± 1.18*	12.57 ± 2.53	7.59 ± 2.04
Brain	0.13 ± 0.03	0.12 ± 0.03	0.06 ± 0.02*	0.03 ± 0.01*	0.07 ± 0.04	0.06 ± 0.01
Blood	3.18 ± 0.51	0.96 ± 0.87	0.32 ± 0.34	0.53 ± 0.17	0.50 ± 0.27	0.11 ± 0.07
Heart	2.10 ± 0.41	0.85 ± 0.16	0.47 ± 0.18*	0.37 ± 0.23*	0.62 ± 0.31	0.39 ± 0.14
Lung	5.31 ± 0.53	1.26 ± 0.32	1.31 ± 0.47	1.12 ± 0.10	1.07 ± 0.42	0.94 ± 0.45
Liver	4.02 ± 0.42	3.17 ± 1.43	2.89 ± 0.25	2.27 ± 0.23	2.91 ± 0.80	1.73 ± 0.33
Skin	4.53 ± 0.88	1.52 ± 0.66	1.14 ± 0.38	0.81 ± 0.13	1.17 ± 0.61	0.78 ± 0.19
Spleen	2.18 ± 0.88	1.23 ± 0.62	0.75 ± 0.37	0.94 ± 0.30	1.14 ± 0.16	0.88 ± 0.30
Stomach	7.61 ± 1.98	2.57 ± 0.38	2.43 ± 0.80	2.64 ± 0.10	2.46 ± 1.39	0.91 ± 0.67
Kidneys	69.37 ± 5.37	67.12 ± 8.79	59.53 ± 9.98	54.24 ± 15.11	69.29 ± 14.34	40.26 ± 10.83
Muscle	0.38 ± 0.17	0.34 ± 0.29	0.21 ± 0.12	0.15 ± 0.06	0.13 ± 0.07	0.23 ± 0.19
Pancreas	1.48 ± 1.24	0.72 ± 0.53	0.44 ± 0.37	0.35 ± 0.19	0.52 ± 0.41	0.25 ± 0.06
Bone	1.53 ± 0.75	1.05 ± 0.31	0.78 ± 0.65	0.37 ± 0.42*	0.98 ± 0.67	0.71 ± 0.39
	Percentage Injected Dose (%ID)
Intestines	3.27 ± 0.13	3.14 ± 1.20	1.97 ± 0.17	1.88 ± 0.16	2.95 ± 0.62	1.13 ± 0.18
Bladder	46.92 ± 2.54	62.26 ± 8.16	75.86 ± 1.75	75.09 ± 3.69	68.69 ± 2.06	78.25 ± 5.29
	Uptake Ratio of Tumor/Normal Tissue
Tumor/Blood	3.48	15.45	5.66	19.81	25.14	69.00
Tumor/Kidneys	0.16	0.22	0.03	0.19	0.18	0.19
Tumor/Lung	2.08	11.77	1.38	9.38	11.75	8.07
Tumor/Liver	2.75	4.68	0.63	4.63	4.32	4.39
Tumor/Muscle	29.11	43.62	8.62	70.00	96.69	33.00

^*p<0.05, significance comparison between ^99mTc-RGD-Lys-(Arg¹¹)CCMSH with or without blockade peptide.